The Inflation Reduction Act created Maximum Fair Price (MFP), a pathway to negotiate drug prices for Medicare beginning with 10 Part D drugs in 2026. This whitepaper outlines how MFP-induced changes to pricing and rebate streams impact Medicare formularies that are submitted to CMS for the 2026 calendar year, with a focus on the impact to MFP drugs.

Hayden-MFP-Medicare-Formulary-Analysis_Whitepaper-2026Jan12

Click here for a printable PDF